Caris Life Sciences’ shares rose after the company released finalized Achieve 1 study results for its multi-cancer early detection test, Caris Detect. The Achieve I study enrolled 3,014 patients, with performance reported across stage I–IV disease and specificity benchmarks for asymptomatic and benign/high-risk groups. Caris reported sensitivity estimates that rise with stage, including stage I and stage II results, alongside specificity for asymptomatic patients and for benign/high-risk categories. The report also noted exclusions based on minimum sample quality metrics and details on the blinded validation set. The company said it expects to launch in the second quarter of 2026 and plans to expand the assay with additional technology such as whole-transcriptome sequencing to strengthen performance.